Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory ...

In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...

Analyst Mike Matson highlighted that the growth story for Boston Scientific depends heavily on its cardiac implant, Watchman.

Needham downgraded Boston Scientific (NYSE:BSX) to Hold from Buy on Friday, noting a potential stagnation in its topline ...

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

周一，TD Cowen对Boston Scientific Corporation (NYSE:BSX)展现了乐观前景，将该公司股票的目标价从86.00美元上调至100.00美元。该机构维持对该股的买入评级，显示出对公司业绩的信心。此次调整是基于预期Boston Scientific将超越第三季度预估，并可能再次上调其指引。

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David ...

Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...

The second wave of the medtech industry’s latest earnings season arrives this week, with Boston Scientific, Edwards ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...